Advertisement

Cancer Immunology, Immunotherapy

, Volume 36, Issue 6, pp 403–408 | Cite as

The development and purification of a bispecific antibody for lymphokine-activated killer cell targeting against the rat colon carcinoma CC531

  • Peter J. K. Kuppen
  • Alexander M. M. Eggermont
  • Katinka M. Smits
  • Jaap D. H. van Eendenburg
  • Sylvia P. G. Lazeroms
  • Cornelis J. H. van de Velde
  • Gert Jan Fleuren
Original articles

Abstract

In vivo targeting of lymphokine-activated killer (LAK) cells to tumour deposits by bispecific monoclonal antibodies (bimAb) may be a way to improve adoptive immunotherapy. We developed a bimAb against adherent LAK (ALAK) cells and colon tumour CC531 in Wag rats. The bimAb was produced by somatic hybridization of two mouse hybridomas, one producing monoclonal antibodies (mAb) against CD8 (IgG2b, OX8), and the other producing mAb against a CC531-associated antigen (IgG1, CC52). A bimAb-producing clone was selected by an enzyme-linked immunosorbent assay with CC531 tumour cells. BimAb were purified from ascitic fluid by protein A affinity chromatography. Each of five pooled peak fractions was analysed by flow cytometry for the presence of bimAb. Most bimAb were found in a fraction that was eluted at pH 4.5 from protein A. FPLC analysis of this fraction revealed that no parental antibodies were present. The OX8 × CC52 bimAb greatly increased conjugate formation in vitro between ALAK cells and CC531. Results of51Cr-release assays with CC531 as target cells and ALAK cells as effector cells were not significantly different in the presence or in the absence of the bimAb. The methods we used here, a cell enzyme-linked immunosorbent assay and flow cytometry, are simple methods for development and purification of a bimAb when a functional selection method is not a priori available. The OX8 × CC52 bimAb we developed this way may increase in vivo tumour targeting of ALAK cells and thus augment antitumour effect in vivo.

Key words

Bispecific monoclonal antibody Lymphokine-activated killer cell Rat CD8 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Basse P, Herberman RB, Nannmark U, Johansson BR, Hokland M, Wasserman K, Goldfarb RH (1991) Accumulation of adoptively transferred adherent, lymphokine-activated killer cells in murine metastases. J Exp Med 174: 479Google Scholar
  2. 2.
    Beun GDM, van Eendenburg JDH, Corver WE, Van de Velde CJH, Fleuren GJ (1992) T-cell retargeting using bispecific monoclonal antibodies in a rat colon carcinoma model. I. Significant bispecific lysis of syngeneic colon carcinoma CC531 is critically dependent on prolonged preactivation of effector T-lymphocytes by immobilized anti-T-cell receptor antibody. J Immunother 11: 238Google Scholar
  3. 3.
    Chambers WH, Vujanovic NL, DeLeo AB, Olszowy MW, Herberman RB, Hiserodt JC (1989) Monoclonal antibody to a triggering structure expressed on rat natural killer cells and adherent lymphokine-activated killer cells. J Exp Med 169: 1373Google Scholar
  4. 4.
    Eggermont AMM, Marquet RL, de Bruin RWF, Jeekel J (1986) Effects of the interferon-inducer ABPP on colon cancer in rats: importance of tumor load and tumor site. Cancer Immunol Immunother 22: 217Google Scholar
  5. 5.
    Felgar RE, Hiserodt JC (1990) In vivo migration and tissue localization of highly purified lymphokine-activated killer cells (A-LAK Cells) in tumor-bearing rats. Cell Immunol 129: 288Google Scholar
  6. 6.
    Ferrini S, Prigione I,Miotti S, Ciccone E, Cantoni C, Chen Q, Colnaghi MI, Moretta L (1991) Bispecific monoclonal antibodies directed to CD16 and to a tumor-associated antigen induce target-cell lysis by resting NK cells and by a subset of NK clones. Int J Cancer 48: 227Google Scholar
  7. 7.
    Carcía de Palazzo I, Gercel-Taylor C, Kitson J, Weiner LM (1990) Potentiation of tumor lysis by a bispecific antibody that binds to CA19-9 antigen and the Fcgamma receptor expressed by human large granular lymphocytes. Cancer Res 50: 7123Google Scholar
  8. 8.
    Gorter A, Krüse KM, Schrier PI, Fleuren GJ, Van de Griend RJ (1992) Enhancement of the lytic activity of cloned human CD8 tumour-infiltrating lymphocytes by bispecific monoclonal antibodies. Clin Exp Immunol 87: 111Google Scholar
  9. 9.
    Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA (1982) Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin-2-activated autologous human peripheral blood lymphocytes. J Exp Med 155: 1823Google Scholar
  10. 10.
    Herberman RB, Hiserodt JC, Vujanovic NL, Balch CM, Lotzová E, Bolhuis RLH, Golub SH, Lanier LL, Phillips JH, Riccardi C, Ritz J, Santoni A, Schmidt RE, Uchida A (1987) Lymphokine-activated killer cell activity. Characteristics of effector cells and their progenitors in blood and spleen. Immunol Today 8: 178Google Scholar
  11. 11.
    Kuppen PJK, Eggermont AMM, Lazeroms SPG, Marinelli A, Van de Velde CJH, Fleuren GJ (1991) The effect of antibodies recognizing adherent-lymphokine-activated killer (ALAK) cells on lysis of P815 and YAC-1 (abstract). Proc Am Assoc Cancer Res 32: 1623Google Scholar
  12. 12.
    Kuppen PJK, Eggermont AMM, Marinelli A, de Heer E, Van de Velde CJH, Fleuren GJ (1991) Induction of lymphokine-activated killer activity in rat splenocyte cultures: the importance of 2-mercaptoethanol and indomethacin. Cancer Immunol Immunother 33: 28Google Scholar
  13. 13.
    Kuppen PJK, Marinelli A, Camps JAJ, Pauwels EKJ, Van de Velde CJH, Fleuren GJ, Eggermont AMM (1992) Biodistribution of lymphokine-activated killer (LAK) cells in Wag rats after hepatic artery or jugular vein infusion. Int J Cancer 52: 266Google Scholar
  14. 14.
    Melder RJ, Walker ER, Herberman RB, Whiteside TL (1990) Surface characteristics, morphology, and ultrastructure of human adherent lymphokine-activated killer cells. J Leukocyte Biol 48: 163Google Scholar
  15. 15.
    Rosenberg SA (1986) Adoptive immunotherapy of cancer using lymphokine activated killer cells and recombinant interleukin-2. In: DeVita Jr. VT, Hellman S, Rosenberg SA (eds) Important advances in oncology 1986. Lippincott, Philadelphia, p 55Google Scholar
  16. 16.
    Rosenberg SA, Lotze MT, Yang JC, Aebersold PM, Linehan WM, Seipp CA, White DE (1989) Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 210: 474Google Scholar
  17. 17.
    Tandon N, Dinsdale C, Tamatani T, Miyasaka M, Weetman AP (1991) Adhesion molecule expression by the FRTL-5 rat thyroid cell line. J Endocrinol 130: 451Google Scholar
  18. 18.
    Titus JA, Perez P, Kaubisch A, Garrido MA, Segal DM (1987) Human K/natural killer cells targeted with hetero-cross-linked antibodies specifically lyse tumor cells in vitro and prevent tumor growth in vivo. J Immunol 139: 3153Google Scholar
  19. 19.
    Van den Brink MRM, Hunt LE, Hiserodt JC (1990) In vivo treatment with monoclonal antibody 3.2.3 selectively eliminates natural killer cells in rats. J Exp Med 171: 197Google Scholar
  20. 20.
    Van Dijk J, Warnaar SO, van Eendenburg JDH, Thienpont M, Braakman E, Boot JHA, Fleuren GJ, Bolhuis RLH (1989) Induction of tumor-cell lysis by bi-specific monoclonal antibodies recognizing renal-cell carcinoma and CD3 antigen. Int J Cancer 43: 344Google Scholar
  21. 21.
    Vujanovic NL, Herberman RB, Maghazachi AA, Hiserodt JC (1988) Lymphokine-activated killer cells in rats. III. A simple method for the purification of large granular lymphocytes and their rapid expansion and conversion into lymphokine-activated killer cells. J Exp Med 167: 15Google Scholar

Copyright information

© Springer-Verlag 1993

Authors and Affiliations

  • Peter J. K. Kuppen
    • 1
  • Alexander M. M. Eggermont
    • 2
  • Katinka M. Smits
    • 1
  • Jaap D. H. van Eendenburg
    • 1
  • Sylvia P. G. Lazeroms
    • 1
  • Cornelis J. H. van de Velde
    • 3
  • Gert Jan Fleuren
    • 1
  1. 1.Department of PathologyUniversity of LeidenLeidenThe Netherlands
  2. 2.Department of SurgeryRotterdam Cancer InstituteRotterdamThe Netherlands
  3. 3.Department of SurgeryUniversity of LeidenLeidenThe Netherlands

Personalised recommendations